Stock Jumping Abnormally High: Abbott Laboratories (NYSE:ABT)

Marco Green
January 13, 2018

The company has market cap of $102.56 billion. Leading up to this report, we have seen a 7.67% rise in the stock price over the last 30 days and a 6.19% increase over the past 3 months. Following the completion of the sale, the chairman now owns 3,677,913 shares in the company, valued at $200,115,246.33. $5.43 million worth of Abbott Laboratories (NYSE:ABT) shares were sold by Salvadori Daniel Gesua Sive. It has underperformed by 0.80% the S&P500. (AMGN) by 35.76% based on its latest 2017Q3 regulatory filing with the SEC. The stock decreased 0.48% or $0.14 during the last trading session, reaching $29.04. Portland Advisors Limited Co accumulated 14,970 shares. CyberArk Software Ltd. (NASDAQ:CYBR) has risen 9.69% since January 10, 2017 and is uptrending.

Many analysts are providing their Estimated Earnings analysis for Abbott Laboratories and for the current quarter 18 analysts have projected that the stock could give an Average Earnings estimate of $0.73/share. Therefore 72% are positive. CF Industries Holdings had 85 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has "Buy" rating given on Friday, January 20 by Bank of America. Goldman Sachs has "Neutral" rating and $90 target. The rating was maintained by Gabelli on Friday, July 21 with "Buy". The rating was upgraded by Morgan Stanley on Tuesday, January 2 to "Overweight". BTIG Research maintained the stock with "Buy" rating in Saturday, August 29 report. The firm has "Outperform" rating by RBC Capital Markets given on Thursday, January 26. As per Thursday, October 19, the company rating was maintained by Morgan Stanley. Guggenheim maintained the shares of ABT in report on Tuesday, January 2 with "Buy" rating. Northland Capital downgraded the stock to "Hold" rating in Thursday, September 28 report. The stock of Abbott Laboratories (NYSE:ABT) earned "Buy" rating by RBC Capital Markets on Thursday, October 19. The firm has "Hold" rating given on Wednesday, June 7 by Bernstein. Leerink Swann also issued estimates for Abbott Laboratories' Q4 2017 earnings at $0.74 EPS, Q3 2018 earnings at $0.78 EPS, FY2018 earnings at $2.85 EPS, FY2019 earnings at $3.17 EPS and FY2021 earnings at $3.93 EPS. Its down 0.16, from 1.15 in 2017Q2. It dropped, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. Sanders Morris Harris LLC boosted its holdings in shares of Abbott Laboratories by 0.3% in the second quarter.

Investors are definitely paying attention to what analysts over at Wall Street are now thinking about the shares of The Williams Companies, Inc. The stock decreased 0.37% or $0.22 during the last trading session, reaching $58.7. Winslow Evans And Crocker holds 114 shares. First Tru Advisors Lp stated it has 0.06% in Abbott Laboratories (NYSE:ABT). St. Louis Trust Co boosted its holdings in Abbott Laboratories by 0.4% during the second quarter. Tealwood Asset Mngmt Inc reported 34,892 shares. Cubic Asset Management Ltd Liability Co has 35,127 shares for 0.53% of their portfolio. Gould Asset Ltd Liability Ca has invested 0.11% in Abbott Laboratories (NYSE:ABT). Srb Corporation reported 1,842 shares.

Since August 1, 2017, it had 0 buys, and 6 selling transactions for $22.86 million activity. Fussell Stephen R also sold $9.73 million worth of Abbott Laboratories (NYSE:ABT) shares. Contreras Jaime sold $2.74 million worth of Abbott Laboratories (NYSE:ABT) on Friday, September 22.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 18th. Abbott Laboratories has a one year low of $39.25 and a one year high of $59.60. ABT's profit will be $1.27 billion for 20.12 P/E if the $0.73 EPS becomes a reality. The healthcare product maker reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.01.

Among 7 analysts covering Assurant (NYSE:AIZ), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 62% are positive. Amgen Inc. had 73 analyst reports since August 3, 2015 according to SRatingsIntel. Oppenheimer maintained, Inc. Timber Creek Cap Mngmt Limited Liability holds 0.02% or 525 shares. Piper Jaffray maintained NIKE, Inc. (NASDAQ:AMZN) rating on Wednesday, October 18. Jefferies has "Buy" rating and $52 target. As per Thursday, August 17, the company rating was initiated by Citigroup. The firm earned "Buy" rating on Wednesday, July 12 by Oppenheimer. The firm earned "Hold" rating on Wednesday, April 5 by Jefferies. (NYSE:CF) for 7,500 shares. The company was maintained on Thursday, July 21 by Goldman Sachs. Puzo Michael J reported 2.24% in Abbott Laboratories (NYSE:ABT). The stock was sold at an average price of $54.41, for a total transaction of $15,065,367.26.

Investors sentiment decreased to 0.87 in 2017 Q3. Its down 0.10, from 1.36 in 2017Q2. 48 funds opened positions while 96 raised stakes. Finally, Country Club Trust Company n.a. lifted its holdings in shares of Abbott Laboratories by 0.5% in the second quarter. Comerica Savings Bank holds 1.11M shares. It also upped Fidelity (FUTY) stake by 25,120 shares and now owns 602,239 shares. Caxton Assoc L P has invested 0.02% in Assurant, Inc. (NASDAQ:AMZN). Chartist Ca has 418 shares. Liberty Mutual Gp Asset Mgmt holds 0.01% of its portfolio in Assurant, Inc. Overall, the share price is down -1.11% year to date. Hikari Power Ltd bought 15,270 shares as the company's stock declined 9.68% while stock markets rallied. Gabelli And Invest Advisers holds 4,500 shares. Weybosset & Ltd Liability Co accumulated 376 shares. Toth Fincl Advisory Corporation accumulated 1.97% or 146,324 shares. Mcdaniel Terry And has 0.11% invested in, Inc. Hbk Invests Limited Partnership reported 68,906 shares. (NASDAQ:AMGN). Guyasuta holds 0.03% of its portfolio in Amgen Inc. (NASDAQ:AMZN) or 216 shares.

Among 5 analysts covering Dialog Semi. (NYSE:CF) to report earnings on February, 21.

Other reports by Click Lancashire

Discuss This Article